Nativi-Nicolau, JoseYilmaz, AliDasgupta, NoelMacey, RichardCochrane, JamesPeatman, JudithSummers, CatherineLuth, JenniferZolty, Ronald2024-09-172024-09-172024Nativi-Nicolau J, Yilmaz A, Dasgupta N, et al. Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review. J Comp Eff Res. 2024;13(7):e230158. doi:10.57264/cer-2023-0158https://hdl.handle.net/1805/43343Aim: The six-minute walk test (6MWT) is a common measure of functional capacity in patients with heart failure (HF). Primary clinical study end points in cardiomyopathy (CM) trials, including transthyretin-mediated amyloidosis with CM (ATTR-CM), are often limited to hospitalization and mortality. Objective: To investigate the relationship between the 6MWT and hospitalization or mortality in CM, including ATTR-CM. Method: A PRISMA-guided systematic literature review was conducted using search terms for CM, 6MWT, hospitalization and mortality. Results: Forty-one studies were identified that reported 6MWT data and hospitalization or mortality data for patients with CM. The data suggest that a greater 6MWT distance is associated with a reduced risk of hospitalization or mortality in CM. Conclusion: The 6MWT is an accepted alternative end point in CM trials, including ATTR-CM.en-USAttribution-NonCommercial-NoDerivatives 4.0 International6MWTATTRCardiomyopathyHospitalizationMortalitySix-minute walk testTransthyretin-mediated amyloidosisArticle